A 69-year-old man was pointed out the anterior mediastinal mass on chest computed tomography (CT). Since the thymoma was suspected, thymectomy was performed through median sternotomy. The tumor was encapsulated and did not directly invade adjacent organs. The tumor was 8.3×5.3×8.2 cm in size. Histological examination of the resected specimen showed a large mucinous component and a small fibrous component, both containing many atypical spindle cells and multinuclear giant cells, and fat cells and atypical lipoblasts observed in a small part of the specimen. The postoperative pathological diagnosis was dedifferentiated liposarcoma. No relapse is observed without adjuvant therapy at 1 year after surgery.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Giant Well-Differentiated Liposarcoma of Esophagus Completely Removed by Endoscopic Submucosal Dissection.
Dig Dis Sci
January 2025
Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, 300# Guangzhou Road, Nanjing, Jiangsu Province, China.
From Images to Insights: Multimodal Imaging for Cardiac Metastases in Myxoid Liposarcomas.
JACC Case Rep
December 2024
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
A Pericardial Mass in a Patient With Recurrent Liposarcoma.
JACC Case Rep
December 2024
Cardiology Hospital, XXI Century National Medical Center, Mexican Social Security Institute, Mexico City, Mexico.
Pericardial and cardiac masses in patients with established malignant neoplasms represent a diagnostic and therapeutic challenge. We present the case of a 66-year-old woman with history of myxoid liposarcoma of the left thigh who had an unexpected recurrence in the pericardium 12 years later.
View Article and Find Full Text PDFSafety and Efficacy of Anlotinib-based Regimen in Patients with Unresectable or Metastatic Bone and Soft-tissue Sarcomas: A Retrospective Institutional Study.
Anticancer Agents Med Chem
January 2025
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Henan Zhengzhou, 450052, China.
Background: Anlotinib has demonstrated durable clinical benefits in patients with unresectable or metastatic bone and soft-tissue sarcomas.
Methods: 92 patients treated with chemotherapy combined with or without anlotinib were collected and analyzed. The objective response rate (ORR) and disease control rate (DCR) were analyzed.
Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma.
Sci Rep
January 2025
School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.
A subgroup analysis of a randomized study demonstrated that patients with advanced or metastatic liposarcoma treated with eribulin had longer overall survival and progression-free survival compared to those treated with dacarbazine, suggesting eribulin as a therapeutic option for advanced liposarcoma. Therefore, this study aims to evaluate the cost-effectiveness of eribulin versus dacarbazine in the treatment of advanced liposarcoma. We established a 10-year Markov model to compare the cost-effectiveness of eribulin and dacarbazine regimens.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!